TesoRx is a privately held pharmaceutical company that has developed an oral therapeutic testosterone formulation called TSX-002, which is designed to treat testosterone deficiency in men. The company's drug delivery platform offers a novel oral testosterone replacement therapy containing testosterone undecanoate, which is safe and effective and helps restore testosterone levels in hypogonadal men. TesoRx is currently completing a phase two clinical study and is on track to commence dosing for phase three by early 2014. The US market for testosterone formulations is currently estimated at $2.1 Billion with prescriptions having grown 90% over five years. Analysts project that the entire testosterone market is expected to hit $5 billion by 2017, and the introduction of a safe and effective oral treatment regimen could cannibalize more than 70% of existing treatments.